0.4988
price down icon4.08%   -0.0212
 
loading

Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie

pulisher
Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025
pulisher
Mar 31, 2025

Tenaya to lay off about one-third of staff, reveals heart gene therapy data - Endpoints News

Mar 31, 2025
pulisher
Mar 31, 2025

Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Undervalued Cardiology Stocks to Watch: TNYA, MIST, BBIO, ALNY - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Tenaya Therapeutics IncOn Mar 27, Co Approves Restructuring PlanSEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

FY2025 Earnings Estimate for TNYA Issued By Chardan Capital - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo

Mar 25, 2025
pulisher
Mar 25, 2025

Top 3 Insider Stock Buys in March—Are They Still Good in April? - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function - Yahoo Finance

Mar 25, 2025
pulisher
Mar 24, 2025

Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st

Mar 24, 2025
pulisher
Mar 24, 2025

Tenaya reports promising gene therapy for heart condition By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Tenaya reports promising gene therapy for heart condition - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Revolutionary Heart Disease Treatment: Gene Therapy Reverses Cardiac Damage in Landmark Study - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Tenaya Therapeutics announces $300M mixed shelf offering; shares down - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Tenaya Therapeutics files for mixed shelf offering of up to $300 mln -March 21, 2025 at 04:16 pm EDT - MarketScreener

Mar 21, 2025
pulisher
Mar 19, 2025

Tenaya Therapeutics to Present New Data on MYBPC3-Associated Hypertrophic Cardiomyopathy at ACC 2025 Annual Scientific Session - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Tenaya Therapeutics Announces Late Breaker and New Data - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Major Breakthrough: Tenaya's Gene Therapy Trial Reveals Critical One-Year Heart Disease Data - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN

Mar 19, 2025
pulisher
Mar 15, 2025

Canaccord Genuity Group Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $6.00 - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Analysts Issue Forecasts for TNYA Q1 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Morgan Stanley Has Lowered Expectations for Tenaya Therapeutics (NASDAQ:TNYA) Stock Price - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $9.00 - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

What is HC Wainwright’s Estimate for TNYA Q1 Earnings? - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Canaccord cuts Tenaya Therapeutics price target to $6 By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Canaccord cuts Tenaya Therapeutics price target to $6 - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Q1 Earnings Forecast for TNYA Issued By Lifesci Capital - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $5.00 at HC Wainwright - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Chardan Adjusts Price Target on Tenaya Therapeutics to $9 From $18, Keeps Buy Rating - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

H.C. Wainwright cuts Tenaya Therapeutics price target to $5 By Investing.com - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

Tenaya Therapeutics Advances Gene Therapy Pipeline - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

H.C. Wainwright cuts Tenaya Therapeutics price target to $5 - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.

Mar 11, 2025
pulisher
Mar 11, 2025

Tenaya Therapeutics SVP sells shares worth $1,334 By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Tenaya Therapeutics chief medical officer sells shares worth $3,982 By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Tenaya Therapeutics chief medical officer sells shares worth $3,982 - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 - Investing.com India

Mar 10, 2025
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):